Episode #15: Nurturing growth: Measuring the return from pharmaceutical innovation 2021

In episode fifteen of the Life Science Connect podcast, we dive into the conversation around our annual R&D Measuring the return from pharmaceutical innovation series report. This report analyses the projected return on investment that biopharma companies can expect to earn from their late-stage pipelines.

On this episode of Life Science’s Connect podcast, we discuss these issues further with our panel of experts:

• Colin Terry, UK Life Sciences and Healthcare Consulting Leader
• Neil Lesser, US Life Sciences R&D Leader

And of course, our host, Karen Taylor, Research Director, Centre for Health Solutions, Deloitte

In episode fifteen of the Life Science Connect podcast, we dive into the conversation around our annual R&D Measuring the return from pharmaceutical innovation series report. This report analyses the projected return on investment that biopharma companies can expect to earn from their late-stage pipelines.

This year, we have witnessed a large improvement in IRR with some companies seeing impressive improvements in peak sales projections. Moreover, the average cost to develop an asset has declined as the industry begins to capitalise on improvements in efficiency.

Find out more

If you are interested in any of the topics discussed during this episode and want more information, please explore some useful links below:

• Stay up to date on industry issues by subscribing to our blog.

Life Sciences Connect

To see the full collections of episodes so far, please visit the Life Sciences Connect podcast library.